Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone

Diabetic Medicine

Volumn 13, Issue 4, 1996, Pages 365-370

  Iwamoto, Y ^a   Kosaka, K ^b   Kuzuya, T ^c   Akanuma, Y ^d   Shigeta, Y ^e   Kaneko, T ^f  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d INSTITUTE FOR ADULT DISEASES   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^f YAMAGUCHI ROSAI HOSPITAL   (Japan)

Author keywords

Insulin action enhancer; Insulin resistance; Oral hypoglycaemic agent; Thiazolidinedione; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; GLIBENCLAMIDE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEW DRUG; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHROMANS; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0030012267     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M     Document Type: Article

References (13)

1. Reaven GM. Insulin secretion and insulin action in non-insulin dependent diabetes mellitus. Which defect is primary? Diabetes Care 1984; 7 (suppl 1): 17-24.
2. Olefsky JM. Pathogenesis of insulin resistance and hyperglycemia in non-insulin dependent diabetes mellitus. Am J Med 1985; 79 (suppl 3B): 1-7.
3. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T. Hasegawa K, et al. Studies on hindered phenols and analogues. 1 .Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 1989; 32: 421-428.
4. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
5. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 1990; 39: 1056-1062.
6. Horikoshi H, Fujiwara T, Yoshioka T, Yoshioka S, Wada M, Fukami M. Pharmacological characteristic of new antidiabetic agent CS-045 in diabetic animals. Frontiers in Diabetic Research 1990; VI 8: 320-324.
7. Akanuma Y, Kosaka K, Shigeta Y, Kuzuya T, Kaneko T, Shimizu N. Clinical evaluation of a new oral hypoglycemic agent CS-045 in Type 2 diabetes. Diabetologia 1992; 35 (suppl 1): A63.
8. Bader S, Kiehn R, Häring H. Effekt von CS 045 auf die Kinaseaktivitat des Insulinrezeptors im Skelettmuskel insulinresistenter Zucker-Ratten. Diabetes und Stoffwechsel 1993; 2: 56-61.
9. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 1994; 43: 447-453.
10. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fujiwara T, et al. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994; 135: 2279-2282.
11. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991; 14: 1083-1086.
12. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
13. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetics is independent of the mode of treatment. Diabetologia 1980; 18: 23-28.